Rare Disease Focused CANbridge Raises $77 Million in IPO on Hong Kong Stock Exchange


Source: globalgenes.org globalgenes.org

Key Topics in this News Article:

News Snapshot:

Rare Daily Staff CANbridge Pharmaceuticals officially listed on the main board of the Stock Exchange of Hong Kong Limited under the ticker 1228.HK, having raised $77 million in an initial public offering. The China-based global rare disease-focused biopharmaceutical company issued 56.3 million shares globally at a final offer price of $1.56 (HK$12.18) per share, raising approximately $77 million (HK$604 million) in net proceeds (excluding the 8,437,000 share over-allotment option, which is subject to exercise). A total of seven well known cornerstone investors participated in the IPO, including: RA Capital, Hudson Bay Master Fund, Janus Investors, General Atlantic, WuXi Biologics, Ruihua...